| 61/425 | US=9 / Urologia Elfiky AA, Kelly WK. Bevacizumab in advanced prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 207-14. ISBN 978-1-60327-831-7. BEVACIZUMAB IN ADVANCED PROSTATE CANCER; ANGIOGENESE; CANCER DE PROSTATA; DROGAS; BEVACIZUMAB |
| 62/425 | US=9 / Urologia Gardner ER, Di Lorenzo G, Figg WD. Thalidomide and analogs. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 215-23. ISBN 978-1-60327-831-7. TALIDOMIDA; LENALIDOMIDA; ANGIOGENESE; CANCER DE PROSTATA; IMUNOMODULADORES |
| 63/425 | US=9 / Urologia Aragon-Ching JB, Dahut W. Investigational angiogenesis inhibitors. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 225-32. ISBN 978-1-60327-831-7. INIBIDORES DA ANGIOGENESE; ANTIANGIOGENESIS; ENSAIOS CLINICOS; CANCER DE PROSTATA; TIROSINA QUINASES |
| 64/425 | US=9 / Urologia Bocci G, Pasqualetti G, Di Paolo A, Crea F, Del Tacca M, Danesi R. Pharmacogenetics of angiogenesis. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 233-42. ISBN 978-1-60327-831-7. TERAPIA ANTIANGIOGENESIS; RISCO DE CANCER; POLIMORFISMOS DE NUCLEOTIDEO UNICO; HIF; MMP; TNF; VEGF |
| 65/425 | US=9 / Urologia Keller ET, Hall CL. Pathophysiology of prostate cancer bone metastasis. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 245-54. ISBN 978-1-60327-831-7. FISIOPATOLOGIA DA PROSTATA; METASTASE OSSEA DO CANCER; CANCER DE PROSTATA; METASTASE OSSEA; RANKL; PROTEINA MORFOGENETICA OSSEA |
| 66/425 | US=9 / Urologia Sartor O, Venugopal DR. Radiopharmaceuticals. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 255-66. ISBN 978-1-60327-831-7. RADIOFARMACOS; SAMARIO-EDTMP; CLORETO DE ESTRONCIO; RADIO; FOSFORO; PALIACAO; CANCER DE PROSTATA; METASTASES OSSEAS; TERAPIA OSSO-ALVO |
| 67/425 | US=9 / Urologia Saylor PJ, Smith MR. Bisphosnates for prevention and treatment of bone metastases. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 267-75. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; METASTASES OSSEAS; ODANACATIB; OSTEOCLASTOS; BISFOSFONATO; ESQUELETICOS RELACIONADOS COM EVENTOS; DENOSUMAB |
| 68/425 | US=9 / Urologia Nelson JB. Endothelin receptors as therapeutic targets in castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 277-86. ISBN 978-1-60327-831-7. RECEPTORES DE ENDOTELINA; CASTRACAO CANCER DE PROSTATA. TERAPIAS; METASTASES OSSEAS; ENSAIOS CLINICOS; RECEPTORES DE ENDOTELINA; ENDOTELINA-1; CANCER DE PROSTATA |
| 69/425 | US=9 / Urologia Jensen AR, Szmulewitz RZ, Beer TM, Posadas EM. Calcitriol and vitamin D analogs. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 287-302. ISBN 978-1-60327-831-7. |
| 70/425 | US=9 / Urologia Madan RA, Gulley JL, Celestin J, Arlen PM, Schlom J. Cancer immunology, immunotherapeutics, and vaccine approaches. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 305-19. ISBN 978-1-60327-831-7. CANCER DE IMUNOLOGIA; IMUNOTERAPIA; VACINA DO CANCER; CANCER DE PROSTATA |
| 71/425 | US=9 / Urologia Higano CS. Sipuleucel-T: autologous cellular immunotherapy for metastatic castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 321-27. ISBN 978-1-60327-831-7. SIPULEUCEL-T; IMUNOTERAPIA CELULAR AUTOLOGA; CANCER DE PROSTATA; METASTATICO RESISTENTE A CASTRACAO; HORMONIO REFRATARIO; PROVENCE; IMUNOTERAPIA CELULAR AUTOLOGA; RESISTENTE A CASTRACAO; APC8015 |
| 72/425 | US=9 / Urologia Patel LR, Simons JW. GM-CSF gene-transduced prostate cancer vaccines: GVAX. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 329-42. ISBN 978-1-60327-831-7. |
| 73/425 | US=9 / Urologia Harzstark AL, Fong L. CTLA-4 blockade for prostate cancer treatment. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 243-8. ISBN 978-1-60327-831-7. |
| 74/425 | US=9 / Urologia Parnes HL, House MG, Tanfrea JA. Prostate cancer chemoprevention strategies. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 351-62. ISBN 978-1-60327-831-7. QUIMIOPREVENCAO DO CANCER DE PROSTATA; QUIMIOPREVENCAO; DESENVOLVIMENTO DE AGENTES; DESFECHOS DO ESTUDO; COORTES; PCPT; REDUCE |
| 75/425 | US=9 / Urologia Chan JM, Richman EL. Diet and prostate cancer incidence, recurrence, and progression risk. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 363-73. ISBN 978-1-60327-831-7. |
| 76/425 | US=9 / Urologia Lucia MS, Lambert JR, Platz EA, Marzo AM. Inflammation as a target in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 375-86. ISBN 978-1-60327-831-7. INFLAMACAO; CANCER DE PROSTATA; CARCINOGENESE; QUIMIOPREVENCAO; QUIMIOTERAPIA; CITOCINAS; INFLAMACAO; ESTRESSE OXIDATIVO |
| 77/425 | US=9 / Urologia Alva AS, Bradley DA, Hussain M. Challenges for the development of new agents in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 389-97. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; NOVOS AGENTES DIRECIONADOS; DESAFIOS; DESENVOLVIMENTO DE MEDICAMENTOS |
| 78/425 | US=9 / Urologia Ning YM, Dagher RN, Pazdur R. FDA approval of prostate cancer treatments. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 399-405. ISBN 978-1-60327-831-7. FDA DOS TRATAMENTOS DO CANCER DE PROSTATA; APROVACAO DE MEDICAMENTOS; DESENVOLVIMENTO DE MEDICAMENTOS; ENDPOINTS; FDA; ANALISE POST-HOC; CANCER DE PROSTATA; ANALISE DE SUBGRUPO; PARAMETROS DE SUBSTITUICAO; SOBREVIVENCIA |
| 79/425 | US=9 / Urologia Gross M, Nepomuceno EM, Agus DB. Applications of proteomics in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 407-17. ISBN 978-1-60327-831-7. PROTEOMICA; CANCER DE PROSTATA; ESPECTROMETRIA DE MASSA; BIOMARCADOR; ANTIGENO PROSTATICO ESPECIFICO; IMUNO-HISTOQUIMICA |
| 80/425 | US=26-A / Radioterapia Lee AK, Pollack A. The prostate. In: Cox JD, Ang KK. Radiation oncology: rationale, technique, results. 9ª ed. Philadelphia: Elsevier Mosby, 2010. p. 676-729. ISBN 978-0-323-04971-9. PROSTATA; CANCER DE PROSTATA; RADIOTERAPIA; TECNICAS RADIOTERAPICAS; BRAQUITERAPIA; PROSTATECTOMIA; CRIOTERAPIA |